Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies-Reference-Cited by-同舟云学术

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Published:2018-02-22 Issue:8 Volume:131 Page:877-887
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Flinn Ian W.¹²,O’Brien Susan³,Kahl Brad⁴,Patel Manish¹⁵,Oki Yasuhiro³,Foss Francine F.⁶,Porcu Pierluigi⁷,Jones Jeffrey⁸,Burger Jan A.³,Jain Nitin³,Kelly Virginia M.⁹,Allen Kerstin⁹,Douglas Mark⁹,Sweeney Jennifer⁹,Kelly Patrick⁹,Horwitz Steven¹⁰

Affiliation:

1. Sarah Cannon Research Institute, Nashville, TN;

2. Tennessee Oncology, Nashville, TN;

3. MD Anderson Cancer Center, Houston, TX;

4. Department of Medicine, Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI;

5. Florida Cancer Specialists, Sarasota, FL;

6. Yale University Cancer Center, New Haven, CT;

7. Division of Hematology, College of Medicine, Ohio State University, Columbus, OH;

8. The Ohio State University Wexner Medical Center, Columbus, OH;

9. Infinity Pharmaceuticals, Inc., Cambridge, MA; and

10. Memorial Sloan-Kettering Cancer Center, New York, NY

Abstract

Key Points Duvelisib, an oral dual inhibitor of PI3K-δ and γ, is clinically and pharmacodynamically active across a range of hematologic malignancies. 75 mg twice daily was determined to be the MTD, with 25 mg twice daily selected for further evaluation in phase 2 and 3 studies.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/8/877/1466916/blood786566.pdf

Reference32 articles.

1. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation;Clayton;J Exp Med,2002

2. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice;Okkenhaug;Science,2002

3. The emerging mechanisms of isoform-specific PI3K signalling;Vanhaesebroeck;Nat Rev Mol Cell Biol,2010

4. Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function;Fung-Leung;Cell Signal,2011

5. Duvelisib (IPI-145) inhibits malignant B-cell proliferation and disrupts signaling from the tumor microenvironment through mechanisms that are dependent on PI3K-δ and PI3K-γ;Peluso;Blood,2014

Cited by 216 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Pyrazolo[1,5-a]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors;Journal of Medicinal Chemistry;2024-08-20

2. Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine;Cancer Biology & Medicine;2024-08-09

3. Targeted small molecule therapy and inhibitors for lymphoma;Future Medicinal Chemistry;2024-07-17

4. Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-07-06

5. A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL);Leukemia & Lymphoma;2024-06-05